Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CRB-701 + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CRB-701 | SYS6002|SYS-6002|SYS 6002|CRB701|CRB 701|Sutantatug envedotin | NECTIN4 Antibody 15 | CRB-701 (SYS6002) is an antibody-drug conjugate (ADC) targeting NECTIN4, which potentially decreases tumor growth (PMID: 42636059). | |
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 139 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06265727 | Phase Ib/II | CRB-701 CRB-701 + unspecified PD-1 antibody | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Recruiting | USA | ROU | ITA | GBR | FRA | ESP | 1 |